These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10683626)

  • 1. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.
    Gervin M; Browne S; Garavan J; Roe M; Larkin C; O'Callaghan E
    Eur Psychiatry; 1999 Nov; 14(7):405-9. PubMed ID: 10683626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].
    Schimmelmann BG; Schacht M; Perro C; Lambert M
    Nervenarzt; 2004 Jan; 75(1):36-43. PubMed ID: 14722660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
    Freudenreich O; Cather C; Evins AE; Henderson DC; Goff DC
    J Clin Psychiatry; 2004 Oct; 65(10):1372-6. PubMed ID: 15491241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490.
    Boerner RJ; Klement S
    Wien Med Wochenschr; 2004 Nov; 154(21-22):508-10. PubMed ID: 15638068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in schizophrenia: insight and subjective response to neuroleptics.
    Browne S; Garavan J; Gervin M; Roe M; Larkin C; O'Callaghan E
    J Nerv Ment Dis; 1998 Feb; 186(2):74-8. PubMed ID: 9484306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia.
    Kim JH; Ann JH; Kim MJ
    Compr Psychiatry; 2010; 51(2):165-70. PubMed ID: 20152297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes.
    Decina P; Mukherjee S; Caracci G; Harrison K
    Am J Psychiatry; 1992 Aug; 149(8):1075-80. PubMed ID: 1353315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M; Hashimoto T; Takamatsu T; Maeda K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapyramidal motor abnormalities associated with late-life psychosis.
    Caligiuri MP; Lohr JB; Panton D; Harris MJ
    Schizophr Bull; 1993; 19(4):747-54. PubMed ID: 7905662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risks of long-term neuroleptic treatment of schizophrenia: especially depression and akinesia.
    Rifkin A
    Acta Psychiatr Scand Suppl; 1981; 291():129-36. PubMed ID: 6113730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
    Singh MM; Kay SR
    Biol Psychiatry; 1979 Apr; 14(2):277-94. PubMed ID: 38865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between akathisia and subjective tolerability in patients with schizophrenia.
    Kim JH; Byun HJ
    Int J Neurosci; 2010 Jul; 120(7):507-11. PubMed ID: 20583904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.